Abstract
Recent experimental and clinical studies have placed new emphasis on the role of the innate immune system in SLE. Nucleic acid-containing immune complexes activate the innate response by engaging specific Toll-like receptors (TLRs) and promote the generation of autoantibodies. Pharmacologic modulation of TLR-directed pathways may offer new therapeutic approaches for the treatment of SLE.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Autoantibodies / blood*
-
CpG Islands / immunology
-
Homeostasis
-
Humans
-
Immunity, Innate
-
Interferon-alpha / metabolism
-
Lupus Erythematosus, Systemic / blood
-
Lupus Erythematosus, Systemic / immunology*
-
Lupus Erythematosus, Systemic / therapy
-
Mice
-
Reactive Oxygen Species
-
Ribonucleoproteins, Small Nuclear / immunology
-
Ribonucleoproteins, Small Nuclear / metabolism*
-
Self Tolerance
-
Signal Transduction / immunology
-
Toll-Like Receptor 7 / immunology
-
Toll-Like Receptor 7 / metabolism*
-
Toll-Like Receptor 9 / immunology
-
Toll-Like Receptor 9 / metabolism*
Substances
-
Autoantibodies
-
Interferon-alpha
-
Reactive Oxygen Species
-
Ribonucleoproteins, Small Nuclear
-
Toll-Like Receptor 7
-
Toll-Like Receptor 9